Results of a prospective controlled two-dose crossover study with intravenous immunoglobulin and comparison (retrospective) with plasma treatment

Bernatowska, Ewa; Madaliński, K; W, Janowicz; R, Weremowicz; Gutkowski, P; Wolf, Hermann M.; Eibl, Martha M.

doi:10.1016/0090-1229(87)90123-1

Cited by 53 publications

(27 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fewer days of infection and less antibiotic treatment were required during high dose therapy. Compared with low-dose IVIG, high-dose IVIG reduced the number of fever days and improved lung function in some patients (Bernatowska et al 1987).…”

Section: Ivig In the United Statesmentioning

confidence: 99%

The history and evolution of immunoglobulin products and their clinical indications

Hooper¹

2015

LymphoSign Journal

View full text Add to dashboard Cite

The history of providing antibodies to treat diseases began in the 19th century with the discovery of tetanus and diphtheria toxins and the demonstration that immunity to tetanus and diphtheria infections could be transferred by immune sera. Characterization of the mediators of this immunity resulted in the discovery that antibodies are proteins that can be isolated and used to protect against infectious diseases. Development of a method to isolate antibodies from human plasma that could be safely injected into people initiated the development of human gamma globulin preparations to provide antibodies to patients with inherited antibody deficiencies. To overcome the limitations imposed by intramuscular injection of gamma globulin, intravenous gamma globulin preparations were developed that began to be used in a wide variety of clinical conditions. Thus the original clinical indication for infection prevention was expanded to several other indications that employ large doses to suppress inflammatory and autoimmune disorders. The most recent development in immunoglobulin therapy is the production of concentrated immune globulins for subcutaneous injection. Home infusions of subcutaneous immunoglobulin are increasingly used to treat immunodeficient patients and are being studied for other clinical applications.

show abstract

Section: Ivig In the United Statesmentioning

confidence: 99%

The history and evolution of immunoglobulin products and their clinical indications

Hooper¹

2015

LymphoSign Journal

View full text Add to dashboard Cite

show abstract

“…IgG treatment was more efficient than plasma therapy in reducing clinical symptoms (Bernatowska et al, 1987), indicating that the biological activity ofthe immunoglobulin applied for treatment is more important than substitution of the respective isotypes. The views on isotype restriction of specific antibodies are not uniform.…”

Section: Discussionmentioning

confidence: 99%

“…The preparation contains approximately 58% IgGl, 40% IgG2 and 2% lgG4, and only trace amounts of IgG3. It has been shown to be efficacious in patients with antibody deficiency syndrome and chronic lung disease in that it improves clinical symptoms and lung function (Bernatowska et al, 1987;Eibl, Cairns & Rosen, 1984). Its anti-inflammatory effect has been documented in patients with Kawasaki syndrome (Newburger et al, 1986).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Clinical efficacy of intravenous immunoglobulin in patients with severe inflammatory chest disease and IgG3 subclass deficiency

Bernatowska

Pac

Skopcynska

et al. 1991

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SUMMARYTo investigate the efficacy of i.v. IgG treatment in pediatric patients with inflammatory lung disease, a prospective, controlled clinical trial was carried out over a 2-year study period. Patients were enrolled on the basis of severe clinical symptomatology. After 1 year of conventional treatment, the patients received 400 mg/kg per month of an i.v. IgG product containing only trace amounts of IgG3 in addition to their regular treatment throughout the second year. Significant clinical improvement, as documented by duration of hospital stay (first year 27 8 days, second year 4 9 days), use of antibiotics (1328 versus 309 days) and use of steroids (21 4 versus 07 days) could be observed. Data obtained on a subgroup of patients with lgG3 deficiency were analysed separately. These results indicate that patients with severe chest disease who have IgG3 deficiency will also benefit from i.v. IgG treatment. The mode of action cannot be attributed to replacement of the respective isotypes, but is probably due to the effect of i.v. IgG in preventing repeated viral infections.

show abstract

“…Gram-negative bacterial pneumonia is a complication that results in high mortality rate occurring especially in patients who have undergone bone marrow transplantation (BMT) [3,4], The therapeutic role of granulocyte transfusions in the treatment of severe infection during neutropenia is con troversial [1,5,6]. Intravenous immunoglobulins (IVIG) are stable monomeric pooled human IgG preparations with opsonic activity [7], Previous reports demonstrated a reduced incidence of bacterial pneumonia following mul tiple trauma in children with AIDS and in patients with primary immunodeficiency syndrome who were treated with IVIG [8][9][10].…”

Section: Introductionmentioning

confidence: 99%

Combined Therapy of Granulocyte Transfusions, Intravenous Opsonins and Antibiotics for Gram-Negative Pneumonia in Neutropenic Cancer Patients

Nagler¹,

Naparstek²,

Engelhard

1994

Acta Haematol

View full text Add to dashboard Cite

Four patients with hematological malignancies, following bone marrow transplantation, who developed documented gram-negative [Klebsiella pneumoniae (2), Pseudomonas aeruginosa or Acinetobacter calcoaceticus] pneumonia during absolute neutropenia, were treated with a combination of antimicrobial therapy, granulocyte transfusions, and high-dose intravenous immunoglobulin. The patients recovered following this regimen, including 2 who had septic shock and respiratory failure, necessitating intubation and mechanical ventilation. These data suggest that therapy combining antimicrobial agents, granulocyte transfusions and opsonins may be effective in neutropenic patients who develop gram-negative pneumonia.

show abstract

Results of a prospective controlled two-dose crossover study with intravenous immunoglobulin and comparison (retrospective) with plasma treatment

Cited by 53 publications

References 5 publications

The history and evolution of immunoglobulin products and their clinical indications

The history and evolution of immunoglobulin products and their clinical indications

Clinical efficacy of intravenous immunoglobulin in patients with severe inflammatory chest disease and IgG3 subclass deficiency

Combined Therapy of Granulocyte Transfusions, Intravenous Opsonins and Antibiotics for Gram-Negative Pneumonia in Neutropenic Cancer Patients

Contact Info

Product

Resources

About